Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Jay Bradner, Murdo Gordon ...
Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.
By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger ...
AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low ...
Scientists in Seoul have uncovered 15 gut bacterial species linked to coronary artery disease, showing that microbes can influence heart health far beyond digestion. Their findings reveal how shifts ...
Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...
8h
The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results